Diet Pill Acomplia (rimonabant) may have a new distressing side-effect, In the 1st edition of the journal Cancer Research Published---according to M.D. Anderson Cancer Center researchers. Researches conducted in mice propose that rimonabant may raise the number and size of polyps that are a precursor of colorectal cancer. The Researcher said their preclinical Study showed that the cannabinoid cell receptor CB1 -- allied with relieving pain and nausea, uplifting mood and motivating appetite -- also appears to play a tumor-suppressing role.
Acomplia (Rimonabant) assist in weight loss by blocking the CB1 receptors peripheral
and central nervous system is approved By the National Institute for Health and Clinical Excellence(NICE) is available in European countries, but due to the risk of side effects that include anxiety and depression, acomplia has been not approved by the Food and
Drug Administration (FDA) and kept away from the U.S. market.
Despite the fact that Acomplia and other same family drugs under development turn CB1 receptors turn off to produce weight-loss, Dr. Raymond DuBois of M.D. Anderson said ….."CB1 back turn on and then treating with a cannabinoid agonist could provide a new approach to colorectal cancer treatment or prevention."
Dubois said ----"Potential application of cannabinoids as anti-tumor medicine is a stimulating prospect, reason cannabinoid agonists are being estimated now to treat the side-effects of chemotherapy and radiation therapy,”
But the researchers also treated the mice with rimonabant, and said …."mice with CB1 blocked in this way also showed a boost in the number and size of polyps."
The researchers said a patient's risk for colorectal cancer should be assessed when use of Acomplia is being considered.
For more information contact : http://www.weightsolution.co.uk/
Acomplia (Rimonabant) assist in weight loss by blocking the CB1 receptors peripheral
and central nervous system is approved By the National Institute for Health and Clinical Excellence(NICE) is available in European countries, but due to the risk of side effects that include anxiety and depression, acomplia has been not approved by the Food and
Drug Administration (FDA) and kept away from the U.S. market.
Despite the fact that Acomplia and other same family drugs under development turn CB1 receptors turn off to produce weight-loss, Dr. Raymond DuBois of M.D. Anderson said ….."CB1 back turn on and then treating with a cannabinoid agonist could provide a new approach to colorectal cancer treatment or prevention."
Dubois said ----"Potential application of cannabinoids as anti-tumor medicine is a stimulating prospect, reason cannabinoid agonists are being estimated now to treat the side-effects of chemotherapy and radiation therapy,”
But the researchers also treated the mice with rimonabant, and said …."mice with CB1 blocked in this way also showed a boost in the number and size of polyps."
The researchers said a patient's risk for colorectal cancer should be assessed when use of Acomplia is being considered.
For more information contact : http://www.weightsolution.co.uk/
